Get the Stockscreener App
0.6837
1.30%
-0.009
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Molluscum Contagiosum Market Expected to rise, 2034 | Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, expected to drive market - Barchart
Barclays PLC Grows Stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Shareholders Can't Ignore US$1.1m Of Sales By Verrica Pharmaceuticals Insiders - Simply Wall St
Verrica Showcases Promising VP-315 Data at Dermatology Conference - MyChesCo
Verrica reports high response rate in skin cancer study - MSN
Verrica Pharmaceuticals Announces Presentation of Three - GlobeNewswire
Verrica reports high response rate in skin cancer study By Investing.com - Investing.com Canada
Verrica's Skin Cancer Drug Shows 97% Response Rate in Phase 2 Trial, Complete Clearance in Half of Tumors - StockTitan
Certain Pre-Funded Warrants of Verrica Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2025. - Marketscreener.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares Bought by Jane Street Group LLC - Defense World
Barclays PLC Grows Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MyChesCo
State Street Corp Buys 61,041 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
60,000 Shares in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Purchased by Sanctuary Advisors LLC - Defense World
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN
Needham & Company LLC Reiterates Hold Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MSN
Verrica reports rise in YCANTH applicator units in Q4 By Investing.com - Investing.com South Africa
Verrica reports rise in YCANTH applicator units in Q4 - Investing.com
Verrica Provides Business and Operational Update - GlobeNewswire
Verrica Pharma's YCANTH Sales Surge in Q4; Plans Game-Changing Single Applicator Launch for 2025 - StockTitan
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
Verition Fund Management LLC Acquires New Holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Position Reduced by Fmr LLC - Defense World
Verrica Pharmaceuticals stock hits 52-week low at $0.7 By Investing.com - Investing.com Canada
Verrica Pharmaceuticals stock hits 52-week low at $0.7 - Investing.com
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Drops By 32.6% - Defense World
Verrica Pharmaceuticals' SWOT analysis: stock faces headwinds amid strategic shift - Investing.com
Verrica Pharmaceuticals' SWOT analysis: stock faces headwinds amid strategic shift By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Inc. Appoints David Zawitz as Chief Operating Officer - Marketscreener.com
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031: Novan Inc., Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals appoints new COO By Investing.com - Investing.com Australia
PERCEPTIVE ADVISORS LLC Increases Stake in Verrica Pharmaceutica - GuruFocus.com
Verrica Pharmaceuticals appoints new COO - Investing.com India
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verrica Pharmaceuticals Appoints New Chief Operating Officer - TipRanks
Verrica's partner Torii seeks Japan NDA for skin treatment By Investing.com - Investing.com Canada
New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208 - MyChesCo
Verrica's partner Torii seeks Japan NDA for skin treatment - Investing.com India
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):